Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep;5(5):428-34.
doi: 10.1097/COH.0b013e32833d17ac.

HIV vaccines: lessons learned and the way forward

Jerome H Kim  1 , Supachai Rerks-Ngarm, Jean-Louis Excler, Nelson L Michael
Affiliations
Review

HIV vaccines: lessons learned and the way forward

Jerome H Kim et al. Curr Opin HIV AIDS. 2010 Sep.

Abstract

Purpose of review: An effective HIV vaccine is a global health priority. We describe lessons learned from four HIV vaccine trials that failed to demonstrate efficacy and one that showed modest protection as a pathway forward.

Recent findings: The Merck Ad5 phase IIb T-cell vaccine failed to show efficacy and might have increased the risk of HIV acquisition in men who have sex with men. Although VaxGen gp120 alone was not efficacious in groups at high risk for HIV-1 infection, the RV144 ALVAC prime and gp120 boost regimen showed 31% efficacy in low-incidence heterosexuals. All trials demonstrated the limitations of available laboratory and animal models to assess relevant vaccine-induced immune responses and predict clinical trial outcome. Analysis of innate and adaptive responses induced in RV144 will guide future trial design.

Summary: Future HIV vaccine trials should define the RV144 immune responses relevant to protection, improve durability and level of protection, and assess efficacy in diverse risk groups. New strategies examining heterologous vector prime-boost, universal inserts, replicating vectors, and novel protein or adjuvant immunogens should be explored to induce T-cell and antibody responses. HIV vaccine development requires innovative ideas and a sustained long-term commitment of scientists, governments, and the community.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. UNAIDS. AIDS epidemic update. Dec, 2009.
    1. Johnston MI, Fauci AS. An HIV vaccine--challenges and prospects. N Engl J Med. 2008;359:888–90. - PubMed
    1. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science. 2008;321:530–2. - PubMed
    1. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455:613–9. - PMC - PubMed
    1. Koff WC. Accelerating HIV vaccine development. Nature. 2010;464:161–2. - PubMed

Publication types